-- Proven population-scale platform delivers best results in rare disease and cancer clinical interpretation, as well as secondary analysis and variant refinement
CAMBRIDGE, Massachusetts, Oct. 14, 2014 /PRNewswire/ -- NextCODE Health, which enables clinicians and scientists to use the full power of the whole genome in real time, today announced that Genomics England (GeL) has invited NextCODE to take part in the analysis of forthcoming whole-genome sequence data across GeL's focus areas in rare diseases and cancer. GeL is expected to begin large-scale sequencing of participants' genomes in the coming months.
The announcement follows GeL's recent 'bake-off' competition among more than two dozen leading analysis providers to identify those that could most effectively find and interpret the key genetic variants underlying rare diseases and cancer. NextCODE outperformed other participants in rare disease interpretation and secondary pipeline analysis, was one of the companies cited for top results in tumor-normal cancer interpretation, and was one of few to compete in all fields being evaluated.
"The 100,000 Genomes Project is a pioneering effort for integrating the use of whole-genome sequencing into better patient care directly through the healthcare system. And our platform, developed in Iceland over the past eighteen years, is uniquely proven for using population-scale sequence data to deliver better diagnostics and pioneering clinical research. We share GeL's vision and hope to help realize it at scale," said Jeffrey Gulcher, MD, PhD, president, chief scientific officer and co-founder of NextCODE.
GeL was established by the UK Department of Health with the aim of sequencing 100,000 whole genomes from around 75,000 volunteer participants by 2017. The project is recruiting NHS patients with common cancers, plus NHS patients with rare diseases and their families.
NextCODE puts the world's most proven sequence analysis platform in the hands of clinicians and researchers around the globe, enabling them to use the full power of NGS data to better diagnose and treat disease. Our solutions combine the only whole-genome analysis system developed at population scale with access to the largest clinical genetics reference database in the world. That gives our partners the ability to solve more cases more efficiently, to store, analyze, visualize and collaborate using all their data – at base-by-base resolution, in real time, from any browser.NextCODE is a private company headquartered in Cambridge, Massachusetts. Visit us on the web at nextcode.com.